Scientific Reports (May 2023)
Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV
- Jae-Yong Kim,
- Kyeongseok Jeon,
- Jung Joo Hong,
- Sang-In Park,
- Hyeonggon Cho,
- Hyo-Jung Park,
- Hye Won Kwak,
- Hyeong-Jun Park,
- Yoo-Jin Bang,
- Yu-Sun Lee,
- Seo-Hyeon Bae,
- So-Hee Kim,
- Kyung-Ah Hwang,
- Dae-Im Jung,
- Seong Hoo Cho,
- Sang Hwan Seo,
- Green Kim,
- Hanseul Oh,
- Hwal-Yong Lee,
- Ki Hyun Kim,
- Hee-Young Lim,
- Pyeonghwa Jeon,
- Joo-Yeon Lee,
- Junho Chung,
- Sang-Myeong Lee,
- Hae Li Ko,
- Manki Song,
- Nam-Hyuk Cho,
- Young-suk Lee,
- So-Hee Hong,
- Jae-Hwan Nam
Affiliations
- Jae-Yong Kim
- Department of Medical and Biological Sciences, The Catholic University of Korea
- Kyeongseok Jeon
- Department of Biomedical Sciences, Seoul National University College of Medicine
- Jung Joo Hong
- Immunology and Infectious Disease Lab, National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)/University of Science and Technology
- Sang-In Park
- SML Biopharm
- Hyeonggon Cho
- Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST)
- Hyo-Jung Park
- Department of Medical and Biological Sciences, The Catholic University of Korea
- Hye Won Kwak
- SML Biopharm
- Hyeong-Jun Park
- Department of Medical and Biological Sciences, The Catholic University of Korea
- Yoo-Jin Bang
- Department of Medical and Biological Sciences, The Catholic University of Korea
- Yu-Sun Lee
- Department of Medical and Biological Sciences, The Catholic University of Korea
- Seo-Hyeon Bae
- Department of Medical and Biological Sciences, The Catholic University of Korea
- So-Hee Kim
- Department of Biomedical Sciences, Seoul National University College of Medicine
- Kyung-Ah Hwang
- Department of Research and Development, Genetree Research
- Dae-Im Jung
- Science Unit, International Vaccine Institute
- Seong Hoo Cho
- Science Unit, International Vaccine Institute
- Sang Hwan Seo
- Science Unit, International Vaccine Institute
- Green Kim
- Immunology and Infectious Disease Lab, National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)/University of Science and Technology
- Hanseul Oh
- Immunology and Infectious Disease Lab, National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)/University of Science and Technology
- Hwal-Yong Lee
- Immunology and Infectious Disease Lab, National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)/University of Science and Technology
- Ki Hyun Kim
- Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine
- Hee-Young Lim
- Center for Emerging Virus Research, National Institutes of Health, Korea Disease Control and Prevention Agency
- Pyeonghwa Jeon
- Center for Emerging Virus Research, National Institutes of Health, Korea Disease Control and Prevention Agency
- Joo-Yeon Lee
- Center for Emerging Virus Research, National Institutes of Health, Korea Disease Control and Prevention Agency
- Junho Chung
- Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine
- Sang-Myeong Lee
- College of Veterinary Medicine, Chungbuk National University
- Hae Li Ko
- Scripps Korea Antibody Institute
- Manki Song
- Science Unit, International Vaccine Institute
- Nam-Hyuk Cho
- Department of Biomedical Sciences, Seoul National University College of Medicine
- Young-suk Lee
- Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST)
- So-Hee Hong
- Department of Microbiology, College of Medicine, Ewha Womans University
- Jae-Hwan Nam
- Department of Medical and Biological Sciences, The Catholic University of Korea
- DOI
- https://doi.org/10.1038/s41598-023-35328-9
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Abstract Severe fever with thrombocytopenia syndrome virus was first discovered in 2009 as the causative agent of severe fever with thrombocytopenia syndrome. Despite its potential threat to public health, no prophylactic vaccine is yet available. This study developed a heterologous prime-boost strategy comprising priming with recombinant replication-deficient human adenovirus type 5 (rAd5) expressing the surface glycoprotein, Gn, and boosting with Gn protein. This vaccination regimen induced balanced Th1/Th2 immune responses and resulted in potent humoral and T cell-mediated responses in mice. It elicited high neutralizing antibody titers in both mice and non-human primates. Transcriptome analysis revealed that rAd5 and Gn proteins induced adaptive and innate immune pathways, respectively. This study provides immunological and mechanistic insight into this heterologous regimen and paves the way for future strategies against emerging infectious diseases.
